Expression of the <i>GST</i>π Gene and Response to Tamoxifen Therapy in Locally Advanced Breast Carcinomas<sup>a</sup>

Dorion-Bonnet, Françoise; Quénel, N.; Coindre, Jean‐Michel; Mauriac, L.; Bonichon, F.; Durand, M.; Wafflart, J.; Moscow, Jeffrey A.; Cowan, Kenneth H.; Gualde, N.

doi:10.1111/j.1749-6632.1993.tb17207.x

Annals of the New York Academy of Sciences

1993

DOI: 10.1111/j.1749-6632.1993.tb17207.x

|View full text |Cite

Expression of the GSTπ Gene and Response to Tamoxifen Therapy in Locally Advanced Breast Carcinomas^a

Françoise Dorion-Bonnet

N. Quénel

Jean‐Michel Coindre

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1993

1996

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This had already been suggested by others (Henry et al, 1989(Henry et al, , 1991Schwartz et al, 1991;Hurlimann et al, 1993;Wilson et al, 1994). We were unable to show a link between response to tamoxifen and c-erbB-2 or GSTi expression, contrary to previous studies (Wright et al, 1992;Nicholson et al, 1993;Dorion-Bonnet et al, 1993).…”

contrasting

confidence: 99%

Variation of hormonal receptor, pS2, c-erbB-2 and GSTπ contents in breast carcinomas under tamoxifen: a study of 74 cases

Soubeyran

Quénel²,

Mauriac³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

Summary Seventy-four post-menopausal patients with primary non-metastatic invasive ductal carcinomas of the breast were first treated with tamoxifen alone (30 mg p.o. daily) for 5 months. To study changes induced by tamoxifen, core biopsies before treatment and surgical specimens after hormonal therapy were assayed by immunohistochemistry for oestrogen (ER) and progesterone receptors (PR), pS2, GSTh and c-erbB-2. After tamoxifen, ER and PR significantly decreased in 60 and 44 cases respectively, whereas 11 and 19 cases showed no variation and 2 and II cases showed an increase (P< 10-4). GSTir and pS2 showed a significant increase in 43 and 41 cases, a decrease in 2 and 21 cases and no variation in 29 and 12 cases (P<.10-4 and P=0.04 respectively). c-erbB-2 showed no significant variation under tamoxifen, increased in only three cases and decreased in 13 cases. No relation was found between these variations and efficiency of hormone therapy. Our results allow a better knowledge of protein expression modifications occurring in breast cancer cells under tamoxifen therapy. They are also more consistent with clone selection rather than with phenotype modification.

show abstract

contrasting

confidence: 99%

Variation of hormonal receptor, pS2, c-erbB-2 and GSTπ contents in breast carcinomas under tamoxifen: a study of 74 cases

Soubeyran

Quénel²,

Mauriac³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

show abstract

Cell biological factors associated with the response of breast cancer to systemic treatment

Klijn¹,

Berns²,

Bontenbal³

et al. 1993

Cancer Treatment Reviews

View full text Add to dashboard Cite

pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients

Soubeyran

Quénel²,

Coindre³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

Summary Tamoxifen as sole initial therapy is gaining importance in the management of post-menopausal breast cancer patients. Age, oestrogen (ER) and progesterone (PR) receptor status are accurately considered to select patients for hormonal treatment. However, additional markers are needed. By immunohistochemistry (IHC), we studied tumour expression of ER, PR, pS2, c-erbB-2 and glutathione S-transferase 7r (GSTh) on initial core biopsies of 208 post-menopausal patients with a non-metastatic invasive ductal carcinoma, treated by neoadjuvant tamoxifen therapy. A good response to tamoxifen was defined as tumoral regression >50% (110 patients). Relationship between response and age, tumour size, T, N, histological grade, ER and PR contents evaluated by radioimmunoassay, ER, PR, pS2, c-erbB-2 and GSTx expression evaluated by IHC were studied. Univariate and multivariate analysis showed that tumoral regression was linked only to pS2 (P = 0.004) and ER (P=0.018) IHC expression. According to the immunohistochemical profile, three groups could be defined: pS2-and ER-positive tumours, pS2-or ER-positive tumours and pS2-and ER-negative tumours with response rates of 60%, 45% and 8% respectively. Although prospective studies are needed to confirm these results, we conclude that pS2 and ER immunohistochemical status are useful tools for predicting tumour regression with neoadjuvant tamoxifen in post-menopausal breast carcinoma patients.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Expression of the GSTπ Gene and Response to Tamoxifen Therapy in Locally Advanced Breast Carcinomas^a

Cited by 3 publications

References 10 publications

Variation of hormonal receptor, pS2, c-erbB-2 and GSTπ contents in breast carcinomas under tamoxifen: a study of 74 cases

Variation of hormonal receptor, pS2, c-erbB-2 and GSTπ contents in breast carcinomas under tamoxifen: a study of 74 cases

Cell biological factors associated with the response of breast cancer to systemic treatment

pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients

Contact Info

Product

Resources

About

Expression of the GSTπ Gene and Response to Tamoxifen Therapy in Locally Advanced Breast Carcinomasa

Cited by 3 publications

References 10 publications

Variation of hormonal receptor, pS2, c-erbB-2 and GSTπ contents in breast carcinomas under tamoxifen: a study of 74 cases

Variation of hormonal receptor, pS2, c-erbB-2 and GSTπ contents in breast carcinomas under tamoxifen: a study of 74 cases

Cell biological factors associated with the response of breast cancer to systemic treatment

pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients

Contact Info

Product

Resources

About

Expression of the GSTπ Gene and Response to Tamoxifen Therapy in Locally Advanced Breast Carcinomas^a